Recent News

• 01.06.2025 - BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe
• 12.27.2024 - TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
• 12.23.2024 - BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
• 12.12.2024 - BeiGene Unveils Breast Cancer Pipeline
• 12.12.2024 - BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

Recent Filings

• 02.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.21.2025 - S-4/A Registration of securities, business combinations
• 01.13.2025 - 8-K Current report
• 01.08.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 01.07.2025 - 144 Report of proposed sale of securities